Niiza, Japan

Fumio Sugawara

This inventor holds 16 USPTO granted patents and 3 EPO patents. Top assignees: Toyo Suisan Kaisha, Ltd., Gunma University, M.t.3, Inc.. Active years: 1990-2023.


% Patents Active = 43.8


Average Co-Inventor Count = 5.4

ph-index = 4

Forward Citations = 48(Granted Patents)


Location History:

  • Niiza, JP (2002 - 2011)
  • Tokyo, JP (1990 - 2023)

Company Filing History:


Years Active: 1990-2023

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents

Title: Fumio Sugawara: Innovator in Porphyrin Compounds

Introduction

Fumio Sugawara is a notable inventor based in Niiza, Japan. He has made significant contributions to the field of chemistry, particularly in the development of porphyrin compounds. With a total of 16 patents to his name, Sugawara's work has implications in various therapeutic applications.

Latest Patents

Among his latest patents are innovative compounds that serve as cancer therapeutic agents, photosensitizers, and fluorescent probes. One of his notable inventions includes a porphyrin compound represented by a specific formula or a salt thereof. Additionally, he has developed a compound represented by another formula, which is characterized by an aliphatic hydrocarbon group containing 10 to 26 carbon atoms.

Career Highlights

Throughout his career, Sugawara has worked with prominent companies such as Toyo Suisan Kaisha, Ltd. and M.t.3, Inc. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in his field.

Collaborations

Sugawara has collaborated with esteemed colleagues, including Kengo Sakaguchi and Takayuki Yamazaki. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Fumio Sugawara's contributions to the field of porphyrin compounds and his extensive patent portfolio highlight his role as a leading inventor. His work continues to influence advancements in cancer therapy and related fields.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…